Literature DB >> 8232226

Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.

R Bai1, Z A Cichacz, C L Herald, G R Pettit, E Hamel.   

Abstract

A highly cytotoxic macrocyclic lactone polyether has been isolated from a Spongia species and named spongistatin 1. With L1210 murine leukemia cells an IC50 value for cell proliferation of 20 pM was obtained, and an increase in the mitotic index concordant with the decrease in cell number was observed. Kangaroo rat kidney PtK1 cells were examined by indirect immunofluorescence with a spongistatin 1 concentration that caused 50% reduction in cellular protein (0.3 nM) and with a 10-fold higher concentration. These cells displayed mitotic and nuclear aberrations at both concentrations, and intracellular microtubules were reduced in number at the lower concentration and disappeared at the higher. Similar changes in PtK1 cells were observed after treatment with equivalent toxic concentrations of the antimitotic agents colchicine, vinblastine, halichondrin B, and dolastatin 10. Spongistatin 1 inhibited the glutamate-induced polymerization of purified tubulin (IC50 value of 3.6 microM versus 2.1 microM for dolastatin 10 and vinblastine and 5.2 microM for halichondrin B). Spongistatin 1 had no effect on the binding of colchicine to tubulin, but it was a potent inhibitor of the binding of vinblastine and GTP to tubulin. In initial experiments with 5 microM tubulin and 5 microM vinblastine, spongistatin 1 and dolastatin 10 both had IC50 values of 2 microM, whereas halichondrin B had an IC50 value of 5 microM. Spongistatin 1 thus represents a new member of the group of complex natural products that inhibit mitosis by binding in the Vinca alkaloid domain of tubulin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8232226

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

Review 1.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

2.  Design, synthesis, and biological evaluation of EF- and ABEF- analogues of (+)-spongistatin 1.

Authors:  Amos B Smith; Christina A Risatti; Onur Atasoylu; Clay S Bennett; Karen Tendyke; Qunli Xu
Journal:  Org Lett       Date:  2010-04-16       Impact factor: 6.005

3.  The solution structure of (+)-spongistatin 1 in DMSO.

Authors:  Onur Atasoylu; George Furst; Christina Risatti; Amos B Smith
Journal:  Org Lett       Date:  2010-04-16       Impact factor: 6.005

Review 4.  Advances in exploring the therapeutic potential of marine natural products.

Authors:  Xiao Liang; Danmeng Luo; Hendrik Luesch
Journal:  Pharmacol Res       Date:  2019-07-25       Impact factor: 7.658

Review 5.  Natural Products in the "Marketplace": Interfacing Synthesis and Biology.

Authors:  Benjamin J Huffman; Ryan A Shenvi
Journal:  J Am Chem Soc       Date:  2019-02-13       Impact factor: 15.419

Review 6.  Conformation-activity relationships of polyketide natural products.

Authors:  Erik M Larsen; Matthew R Wilson; Richard E Taylor
Journal:  Nat Prod Rep       Date:  2015-08       Impact factor: 13.423

Review 7.  The Role of Spongia sp. in the Discovery of Marine Lead Compounds.

Authors:  Patrícia Máximo; Luísa M Ferreira; Paula Branco; Pedro Lima; Ana Lourenço
Journal:  Mar Drugs       Date:  2016-07-23       Impact factor: 5.118

Review 8.  Mechanism targeted discovery of antitumor marine natural products.

Authors:  Dale G Nagle; Yu-Dong Zhou; Flor D Mora; Kaleem A Mohammed; Yong-Pil Kim
Journal:  Curr Med Chem       Date:  2004-07       Impact factor: 4.530

Review 9.  Potential clinical applications of halichondrins in breast cancer and other neoplasms.

Authors:  Vanesa Ortega; Javier Cortés
Journal:  Breast Cancer (Dove Med Press)       Date:  2012-02-08

Review 10.  Impact of marine drugs on animal reproductive processes.

Authors:  Francesco Silvestre; Elisabetta Tosti
Journal:  Mar Drugs       Date:  2009-11-06       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.